CY1108218T1 - Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα - Google Patents

Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα

Info

Publication number
CY1108218T1
CY1108218T1 CY20081100781T CY081100781T CY1108218T1 CY 1108218 T1 CY1108218 T1 CY 1108218T1 CY 20081100781 T CY20081100781 T CY 20081100781T CY 081100781 T CY081100781 T CY 081100781T CY 1108218 T1 CY1108218 T1 CY 1108218T1
Authority
CY
Cyprus
Prior art keywords
methyl
hexyloxycarbonylamino
phenylamino
imino
carbonyl
Prior art date
Application number
CY20081100781T
Other languages
English (en)
Inventor
Anja Kohlrausch
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of CY1108218T1 publication Critical patent/CY1108218T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά ένα νέο δισκίο για τη δραστική ουσία 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1-μεθυλο-1Η-βενζιμιδαζο-λο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικό αιθυλεστέρα και τα φαρμακολογικά αποδεκτά άλατα της.
CY20081100781T 2003-08-16 2008-07-28 Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα CY1108218T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10337697A DE10337697A1 (de) 2003-08-16 2003-08-16 Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
EP04763952A EP1658056B1 (de) 2003-08-16 2004-08-10 Tablette enthaltend 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen salze

Publications (1)

Publication Number Publication Date
CY1108218T1 true CY1108218T1 (el) 2014-02-12

Family

ID=34201585

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100781T CY1108218T1 (el) 2003-08-16 2008-07-28 Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα

Country Status (17)

Country Link
US (1) US20050038077A1 (el)
EP (1) EP1658056B1 (el)
JP (1) JP4977462B2 (el)
AR (1) AR045732A1 (el)
AT (1) ATE394094T1 (el)
CA (1) CA2535810C (el)
CY (1) CY1108218T1 (el)
DE (2) DE10337697A1 (el)
DK (1) DK1658056T3 (el)
ES (1) ES2307041T3 (el)
PE (1) PE20050342A1 (el)
PL (1) PL1658056T3 (el)
PT (1) PT1658056E (el)
SI (1) SI1658056T1 (el)
TW (1) TW200509996A (el)
UY (1) UY28468A1 (el)
WO (1) WO2005018615A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
CL2007002068A1 (es) * 2006-07-17 2008-01-18 Boehringer Ingelheim Int Uso de dabigatran, etexilato de dabigatran, (n-2-piridil-n-2-etoxicarboniletil)amida del acido 1-metil-2-[4-(n-hidroxiamidino)fenilaminoetil]bencimidazol-5-il-carboxilico, melagatran, ximelagatran, hirudina, hirulog y argatroban para el tratamiento de infarto cerebral, infarto de miocardio, trombosis, embolia pulmonar, entre otras.
CN101980697A (zh) * 2008-03-28 2011-02-23 贝林格尔.英格海姆国际有限公司 制备口服给药的达比加群制剂的方法
NZ589746A (en) * 2008-07-14 2012-10-26 Boehringer Ingelheim Int Method for manufacturing medicinal compounds containing dabigatran
PE20110591A1 (es) 2008-07-28 2011-09-15 Takeda Pharmaceutical Composicion farmaceutica estabilizada a base de un compuesto no peptidico
HUP1000069A2 (en) * 2010-02-02 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag New salts for the preparation of pharmaceutical composition
JP2013521318A (ja) 2010-03-08 2013-06-10 ラティオファルム ゲー・エム・ベー・ハー ダビガトランエテキシラートを含有する医薬組成物
PT2588090T (pt) 2010-07-01 2017-06-26 Krka Tovarna Zdravil D D Novo Mesto Formas de dosagem oral farmacêuticas compreendendo dabigatrano etexilato e os seus sais farmaceuticamente aceitáveis
US20140294959A1 (en) 2011-05-20 2014-10-02 Astrazeneca Uk Limited Pharmaceutical Composition of Rosuvastatin Calcium
WO2012162492A1 (en) 2011-05-24 2012-11-29 Teva Pharmaceutical Industries Ltd. Compressed core comprising organic acids for a pharmaceutical composition
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
ES2895918T3 (es) 2012-02-21 2022-02-23 Towa Pharmaceutical Europe S L Composiciones farmacéuticas orales de dabigatrán etexilato
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
KR101609105B1 (ko) * 2012-09-19 2016-04-04 다이호야쿠힌고교 가부시키가이샤 용출성 및/또는 흡수성이 개선된 경구 투여용 의약 조성물
WO2014060545A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of dabigatran free base
WO2014060561A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
CN103230378B (zh) * 2013-05-10 2014-12-10 青岛双鲸药业有限公司 一种氯雷他定片的制备方法
EP2853260A1 (en) * 2013-09-27 2015-04-01 ratiopharm GmbH Pharmaceutical preparation comprising dabigatran etexilate bismesylate
CN104784147B (zh) * 2014-01-20 2018-01-23 成都苑东生物制药股份有限公司 一种甲磺酸达比加群酯胶囊药物组合物及其制备方法
IN2014MU01042A (el) 2014-03-26 2015-10-02 Cadila Healthcare Ltd
EP4205743A1 (en) 2014-12-31 2023-07-05 Shenzhen Pharmacin Co., Ltd. Pharmaceutical composition and preparation method therefor
WO2017103945A1 (en) * 2015-12-15 2017-06-22 Strides Shasun Limited Pharmaceutical compositions
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
EP3332771A1 (en) 2016-12-07 2018-06-13 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayered tablet compositions of dabigatran
JP2018104425A (ja) * 2016-12-26 2018-07-05 日本ケミファ株式会社 ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する錠剤
JP2018184375A (ja) * 2017-04-27 2018-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ダビガトランエテキシラート又は医薬的に許容されるその塩を含む錠剤及びその製造方法
TR201706848A2 (tr) 2017-05-10 2018-11-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabigatran eteksi̇lat i̇çeren kati oral farmasöti̇k kompozi̇syonlar
WO2019004980A2 (en) 2017-05-10 2019-01-03 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE
TR201722323A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin oral farmasöti̇k kompozi̇syonlari
TR201722186A2 (tr) 2017-12-27 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dabi̇gatranin farmasöti̇k kompozi̇syonlari
TR201722630A2 (el) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
HU191542B (en) * 1983-04-08 1987-03-30 Boehringer Ingelheim Ltd Process for production of pastiles containing dipyridamel independent from ph with regulated output of the active substance
CH674148A5 (el) * 1986-06-24 1990-05-15 Racz Istvan
FR2745500B1 (fr) * 1996-03-04 1998-04-03 Synthelabo Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
PT1870100E (pt) * 2002-03-07 2012-04-17 Boehringer Ingelheim Int Metanossulfonato de 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CA2535810A1 (en) 2005-03-03
US20050038077A1 (en) 2005-02-17
WO2005018615A1 (de) 2005-03-03
SI1658056T1 (sl) 2008-08-31
TW200509996A (en) 2005-03-16
PE20050342A1 (es) 2005-06-17
ES2307041T3 (es) 2008-11-16
DE502004007069D1 (en) 2008-06-19
PT1658056E (pt) 2008-06-23
JP4977462B2 (ja) 2012-07-18
UY28468A1 (es) 2005-03-31
EP1658056B1 (de) 2008-05-07
ATE394094T1 (de) 2008-05-15
PL1658056T3 (pl) 2008-10-31
DK1658056T3 (da) 2008-09-08
AR045732A1 (es) 2005-11-09
DE10337697A1 (de) 2005-03-24
JP2007502788A (ja) 2007-02-15
CA2535810C (en) 2013-06-25
EP1658056A1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
CY1108218T1 (el) Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα
CY1113158T1 (el) Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
TW200716610A (en) Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
ME00340B (me) ETIL 3-[(2-{[4-(HEKSILOKSIKARBONILAMINO-IMINO-METIL)-FENILAMINO]-METIL}-l-METIL-IH-BENZIMIDAZOL-5-KARBONIL)-PIRIDIN-2-IL-AMINO]-PROPIONAT-METANSULFONAT I NJEGOVA PRIMJENA KAO LIJEKA
WO2012001156A3 (en) Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
RS52189B (en) 5-LIPOKSIGENAZA-ACTIVIRAJUĆEG PROTEINA (FLAP) INHIBITORIES
NO20075862L (no) Polymorfer av etyl-3-[(2-{[4-(heksyloksykarbonylamino-iminometyl)fenylamino]metyl}-1-metyl-1H-benzimidazol-5-karbonyl)pyridin-2-ylamino]propionat
CL2009001311A1 (es) Procedimiento para preparar {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)metanona a partir de (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona y 1-azidometil-3,5-bistrifluorometilbenceno en presencia de una base y un disolvente (div.sol.2680-04).
ITME20050008A1 (it) Sistema che consente rilascio di nicotina per aspirazione, destinato ai fumatori di sigarette.
NO20052474L (no) Amort form av esomeprazolsalter
EA200901039A1 (ru) Способ получения производного бензимидазола
IL216704A0 (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
DK1509227T3 (da) En bufferet, flydende nikotinsammensætning til pulmonal indgivelse
DK2327692T5 (da) 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-)aryl-substituerede 1-H-pyrrol-derivater som syresekretionshæmmere.
CL2007002218A1 (es) Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
NO20050676L (no) Krystallinsk 2,5-dion-3-(1-metyl-lH-indol-3-yl)-4-[1-(pyridin-2-ylmetyl)piperidin-4-yl]-1H-indol-3-yl]-IH-pyrrol monohydroklorid.
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
CY1111919T1 (el) Ηλεκτρικο αλας της 2-((4-(1-μεθυλ-4-(πυριδιν-4-υλ)-1η-πυραζολ-3-υλ)-φαινοξυ)μεθυλ)κινολινης
ITBO20030076A1 (it) Macchina per la realizzazione di confezioni strip.
UA95601C2 (ru) Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1метил-1н- бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и фармацевтическая композиция, которая его содержит
WO2008026765A3 (en) Lyophilized preparation
TW200833325A (en) Pharmaceutical composition comprising ascorbic acid
TH155656A (th) เกลือและรูปของแข็งของ(s)-3-(4-((4-มอร์ฟอลิโนเมธิล)เบนซิล)ออกซิ)-1-ออกโซไอโซอินโดลิน-2-อิล)ไพเพอริดีน-2,6-ไดโอน และองค์ประกอบซึ่งประกอบรวมด้วย และวิธีของการใช้สารเดียวกัน
SE0502461L (sv) Tobaksprodukt
ITTO20021107A1 (it) Involucro scatolato ad elevato isolamento termico.